2 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow BI 836880: new trials by email Literature Review of BI 836880 trials Research Report on BI 836880
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer BI 754091, BI 836880 - Anal Canal Squamous Cell Carcinoma | Phase 2 | Withdrawn | Boehringer Ingelheim | 2020-09-14 | 2021-11-15 | |
| A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) BI 836880 - Wet Macular Degeneration | Phase 1 / Phase 2 | Completed | Boehringer Ingelheim | 43 | 2019-06-27 | 2024-11-20 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | Boehringer Ingelheim | 211 | 2019-03-19 | 2026-01-27 |
Neoplasm Metastasis (1) · Wet Macular Degeneration (1)
United Kingdom (2) · United States (2) · Canada (1) · Germany (1) · South Korea (1)
2017 (1), 2018 (1), 2019 (1)